Cancer research
Men with genes that increase their risk of prostate cancer should have annual checks from the age of 40, research has shown. The Institute of Cancer Research study found that men carrying particular BRCA gene mutations are at an even higher risk of developing aggressive prostate disease. The UK National
Cancer
Researchers at the University of Oxford have published a new report on cancer gene therapy, shedding light on the complexities of hepatitis B virus (HBV) and its role in liver disease and cancer. According to the study, HBV is a global health problem with over 250 million infections, and current
Cancer
Researchers from China have detailed a novel concept in cancer treatment, integrating two distinct immunotherapeutic modalities to overcome the limitations of current therapies. The approach, known as Dual Distinct Immunotherapy (DDI), strategically combines different treatments to achieve a synergistic effect. This review highlights the potential of DDI in enhancing therapeutic
Cancer
Investigators at the University of California have published a new report on biotechnology and cancer gene therapy, revealing a promising strategy for targeting cancers driven by herpesviruses. The research team has devised a cancer gene therapy vector using the adeno-associated virus (AAV), which capitalizes on the latency-associated nuclear antigen (LANA)
Cancer
Researchers at Guangzhou Medical University have uncovered a crucial regulator of hierarchical cellular transitions in hepatocellular carcinoma (HCC), highlighting a potential target for cancer therapy. By analyzing public datasets and in vitro and in vivo models, the team identified the FOXM1/CEBPB axis as a key driver of developmental heterogeneity
Cancer research
Researchers at the Govind Ballabh Pant Institute of Postgraduate Medical Education and Research (GIPMER) in New Delhi, India, have investigated the role of Notch gene receptors in colorectal cancer (CRC) development. The study, published in Scientific Reports, found that polymorphisms in Notch1, Notch2, Notch3, and Notch4 genes are associated with
Cancer research
Pancreatic cancer, characterized by a profoundly immunosuppressive tumor microenvironment, has a poor prognosis. Researchers at the Sichuan Cancer Hospital studied the role of dendritic cells (DCs) in pancreatic cancer and identified a novel DC-related gene signature that stratifies patient subtypes and implicates a KCTD14-TNF signaling axis. This study provides a
Cancer
Research at Aarhus University in Denmark has shed light on the potential of vesicular stomatitis virus (VSV) as a cancer therapy. Studies have shown that VSV selectively replicates in tumor cells while sparing normal cells, making it a promising candidate for cancer treatment. To mitigate neurotoxicity and improve therapeutic efficacy,
Cancer
Researchers at St. Jude Children's Research Hospital have made a groundbreaking discovery about the role of mitochondrial DNA (mtDNA) mutations in cancer growth and therapy resistance. By combining computational tools and DNA sequencing technologies, the team was able to examine mtDNA mutations in cancer cells and pinpoint when
Cancer
Scientists at Taras Shevchenko National University Kyiv have made a significant discovery in the field of biotechnology, specifically in cancer gene therapy. Researchers have found that phospholipid-derived nanocarriers can be used to deliver drugs to cancer cells, offering a new approach to targeted therapy. These nanocarriers are versatile and chemically
Cancer
Research conducted by scientists at Maharishi Markandeshwar (Deemed to be University) has led to a new understanding of siRNA-based therapy for cancer treatment. The study highlights the potential of nanoparticle-based drug delivery systems in effectively targeting cancer cells while overcoming resistance mechanisms. The research also emphasizes the adaptability of carriers
Cancer
Researchers from the Fred Hutchinson Cancer Research Center have conducted the largest-scale cross-protocol immunogenicity comparison to date, examining 13 HIV vaccine trials conducted across nine countries worldwide. The study analyzed 36 vaccine regimens, including a polyvalent DNA prime + protein boost regimen (HVTN 124) that demonstrated exceptional immunogenicity. This regimen induced
